RxDoctor Payments Data

Cassandra Kilpatrick

Pediatrics · Omaha, NENPI 1548748320

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 26.9% of the total. 2025 is the largest year on record at $726, more than ten times the $42 reported in 2022.

$1,647in general payments, 2019–2025

Across 91 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$444
  • AstraZeneca$170
  • Lilly USA, LLC$166
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$121
  • Novo Nordisk$112
  • Pfizer$103
  • plus $530 from 18 others

What the payments were for

  • Food & beverage$1,647100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,647 in reported general payments places this provider in the 85th percentile of 308 pediatrics providers in Nebraska.

See all pediatrics providers in Nebraska

Medicare billing

Part B allowed, 2024
$25,040
Medicare patients
124
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$31,837
EliquisApixaban27$25,328
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$17,098
JardianceEmpagliflozin12$14,317
Fluticasone Propionate27$590
Albuterol Sulfate HfaAlbuterol Sulfate19$499
Gabapentin24$437
Bupropion XlBupropion Hcl11$384
Potassium Chloride18$357
Omeprazole29$353
Atorvastatin Calcium57$321
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$277
Levothyroxine Sodium35$272
Mirtazapine13$250
Lisinopril48$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$112$31,83726 claims
PfizerEliquis$103$25,32827 claims
Boehringer IngelheimJardiance$73$14,31712 claims
Almatica Pharma LLCSertraline Hcl$18$16824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 pediatrics providers in Nebraska.

Other pediatrics in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →